The present disclosure relates to docosapentaneoic acid (DPA) of the omega-3 type (DPA 22:5n-3) or derivative thereof and its use in reducing hypertriglyceridemia in a subject in need thereof. In particular, the disclosure relates to the ability of n-3 DPA to significantly decrease the incorporation of fatty acids in chylomicrons in the post-prandial setting.
